ArticleMedicine2026
Mac-2 binding protein glycosylation isomer contributes to identify advanced Fontan-associated liver disease: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The usefulness of several noninvasive assessments for evaluating liver fibrosis has been reported in Fontan-associated liver disease (FALD). However, no studies have reported on the usefulness of Mac-2 binding protein glycosylation isomer (M2BPGi) in FALD. Here, we investigated the usefulness of M2BPGi in identifying advanced FALD. This retrospective study included patients diagnosed with FALD. Based on the clinical signs of portal hypertension, we defined advanced FALD as a varices, ascites, splenomegaly, and thrombocytopenia (VAST) score ≥ 2, and we compared the cardiac parameters, liver parameters, and serological fibrosis markers, including M2BPGi. The Mann-Whitney U and Fisher exact test were used to compare variables. Spearman rank correlation coefficients (r) were calculated to evaluate correlations. The accuracy of outcome prediction was evaluated using the area under the receiver operating characteristic curve (AUROC). A total of 43 patients with FALD were enrolled. There were 22 cases (51%) diagnosed with advanced FALD. In the serological fibrosis markers, M2BPGi levels were significantly higher in cases with advanced FALD (median 0.65 vs 0.38 cutoff index [C.O.I], P = .003), similar to the fibrosis-4 (FIB-4) index and aspartate aminotransferase (AST) to platelet ratio index (APRI). Receiver operating characteristic analysis revealed that M2BPGi demonstrated moderate ability to predict the cases with advanced FALD (AUROC, 0.767), and the cutoff value was 0.64 C.O.I. Moreover, M2BPGi demonstrated a significant correlation with AST (r = 0.321, P = .036), albumin (r = -0.562, P < .001), FIB-4 index (r = 0.492, P = .001), APRI (r = 0.399, P = .008), and cardiac parameters such as central venous pressure (r = 0.413, P = .006) and brain natriuretic peptide (r = 0.431, P = .004). Esophagogastric varices (31% vs 3%, P = .024) and ascites (69% vs 27%, P = .016) were more prevalent in the higher M2BPGi group. Furthermore, there was a significant trend in increasing M2BPGi with worsening the VAST scores (P = .021). This study suggests that M2BPGi may be useful for identifying advanced FALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.